BR112019023014A2 - constructos de lamp aperfeiçoados compreendendo antígenos de câncer - Google Patents
constructos de lamp aperfeiçoados compreendendo antígenos de câncer Download PDFInfo
- Publication number
- BR112019023014A2 BR112019023014A2 BR112019023014A BR112019023014A BR112019023014A2 BR 112019023014 A2 BR112019023014 A2 BR 112019023014A2 BR 112019023014 A BR112019023014 A BR 112019023014A BR 112019023014 A BR112019023014 A BR 112019023014A BR 112019023014 A2 BR112019023014 A2 BR 112019023014A2
- Authority
- BR
- Brazil
- Prior art keywords
- lamp constructs
- improved lamp
- constructs
- cancer antigens
- improved
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 229940031348 multivalent vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
a presente invenção fornece constructos de lamp aperfeiçoados compreendendo fragmentos específicos do domínio luminal de lamp para liberar antígenos de câncer às células imunes para processamento acentuado. estes constructos de lamp podem ser usados para o tratamento de doenças e, em particular, transtornos hiperproliferativos e/ou câncer. os constructos de lamp aperfeiçoados permitem a apresentação de epítopos tridimensionais adequadamente configurados para a produção de uma resposta imune quando administrados a um indivíduo. os constructos de lamp aperfeiçoados podem ser moléculas multivalentes e/ou podem ser fornecidos como parte de uma vacina multivalente contendo dois ou mais constructos de lamp. os constructos de lamp aperfeiçoados, conforme descrito neste relatório, também podem ser usados para gerar anticorpos quando administrados a um vertebrado não humano.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762500053P | 2017-05-02 | 2017-05-02 | |
US201762561760P | 2017-09-22 | 2017-09-22 | |
PCT/US2018/030725 WO2018204534A1 (en) | 2017-05-02 | 2018-05-02 | Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019023014A2 true BR112019023014A2 (pt) | 2020-05-19 |
Family
ID=62528827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019023014A BR112019023014A2 (pt) | 2017-05-02 | 2018-05-02 | constructos de lamp aperfeiçoados compreendendo antígenos de câncer |
Country Status (10)
Country | Link |
---|---|
US (1) | US20200087365A1 (pt) |
EP (1) | EP3618854A1 (pt) |
JP (3) | JP7222915B2 (pt) |
KR (2) | KR20200016224A (pt) |
CN (1) | CN110913892A (pt) |
AU (1) | AU2018263923B9 (pt) |
BR (1) | BR112019023014A2 (pt) |
CA (1) | CA3061950A1 (pt) |
IL (2) | IL270271B2 (pt) |
WO (1) | WO2018204534A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019222281A1 (en) * | 2018-05-15 | 2019-11-21 | Immunomic Therapeutics, Inc | Improved lamp constructs comprising allergens |
AU2020366515A1 (en) * | 2019-10-18 | 2022-04-21 | Immunomic Therapeutics, Inc. | Improved lamp constructs comprising cancer antigens |
TWI828126B (zh) * | 2021-04-27 | 2024-01-01 | 中央研究院 | 用以治療高三酸甘油脂血症或其相關疾病的方法 |
AU2023254186A1 (en) | 2022-04-10 | 2024-10-17 | Immunomic Therapeutics, Inc. | Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4237115A (en) | 1977-11-23 | 1980-12-02 | Bactex, Inc. | Method of immunization against enterotoxogenic infection by Escherichia coli |
US4397844A (en) | 1978-02-24 | 1983-08-09 | Ciba-Geigy Corporation | Antigen derivatives and processes for their preparation |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
GB2026340B (en) | 1978-07-03 | 1982-12-22 | Ash P | Stabilising microvesicles |
US4681762A (en) | 1979-05-23 | 1987-07-21 | Research Corporation | Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4593002A (en) | 1982-01-11 | 1986-06-03 | Salk Institute Biotechnology/Industrial Associates, Inc. | Viruses with recombinant surface proteins |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4592002A (en) | 1983-12-13 | 1986-05-27 | Honeywell Inc. | Method of digital temperature compensation and a digital data handling system utilizing the same |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
ZA858044B (en) | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
FR2583429B1 (fr) | 1985-06-18 | 1989-11-03 | Transgene Sa | Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u |
AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
DE3642912A1 (de) | 1986-12-16 | 1988-06-30 | Leybold Ag | Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5744166A (en) | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
US5100587A (en) | 1989-11-13 | 1992-03-31 | The United States Of America As Represented By The Department Of Energy | Solid-state radioluminescent zeolite-containing composition and light sources |
JP3068180B2 (ja) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | 異種抗体の生成 |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
AU667460B2 (en) | 1990-10-05 | 1996-03-28 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
ATE160379T1 (de) | 1990-10-29 | 1997-12-15 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
US5179993A (en) | 1991-03-26 | 1993-01-19 | Hughes Aircraft Company | Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid |
WO1992019973A1 (en) | 1991-04-26 | 1992-11-12 | Surface Active Limited | Novel antibodies, and methods for their use |
SE503225C2 (sv) | 1991-10-30 | 1996-04-22 | Leif Lindholm Konsult Ab | Virus-antikroppskomplex för införing av virus i mammalieceller |
US5661133B1 (en) | 1991-11-12 | 1999-06-01 | Univ Michigan | Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
CA2452130A1 (en) | 1992-03-05 | 1993-09-16 | Francis J. Burrows | Methods and compositions for targeting the vasculature of solid tumors |
WO1993025788A1 (en) | 1992-06-09 | 1993-12-23 | Hoppe Ag | Latch and lockset system |
GB9213033D0 (en) | 1992-06-19 | 1992-08-05 | British Telecomm | Method of controlling a telecommunications network |
US5747323A (en) | 1992-12-31 | 1998-05-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Retroviral vectors comprising a VL30-derived psi region |
US5633234A (en) | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
FR2707091B1 (fr) | 1993-06-30 | 1997-04-04 | Cohen Haguenauer Odile | Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes. |
US5928944A (en) | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
ZA951877B (en) | 1994-03-07 | 1996-09-09 | Dow Chemical Co | Bioactive and/or targeted dendrimer conjugates |
WO1995028494A1 (en) | 1994-04-15 | 1995-10-26 | Targeted Genetics Corporation | Gene delivery fusion proteins |
FR2719316B1 (fr) | 1994-04-28 | 1996-05-31 | Idm | Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules. |
CA2193954A1 (en) | 1994-06-27 | 1996-01-04 | Vu L. Truong | Targeted gene delivery system |
FR2722506B1 (fr) | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
EP0805628B1 (en) | 1995-01-17 | 2003-05-02 | Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
FR2737222B1 (fr) | 1995-07-24 | 1997-10-17 | Transgene Sa | Nouveaux vecteurs viraux et lignee pour la therapie genique |
WO1997035996A1 (en) | 1996-03-25 | 1997-10-02 | Transgene S.A. | Packaging cell line based on human 293 cells |
AU3447097A (en) | 1996-07-01 | 1998-01-21 | Rhone-Poulenc Rorer S.A. | Method for producing recombinant adenovirus |
AU3739697A (en) | 1996-07-09 | 1998-02-02 | Johns Hopkins University, The | Gene delivery system |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
KR20080059467A (ko) | 1996-12-03 | 2008-06-27 | 아브게닉스, 인크. | 복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체 |
IL130198A (en) | 1996-12-13 | 2005-09-25 | Schering Corp | Methods for purifying viruses |
FR2759382A1 (fr) | 1997-02-10 | 1998-08-14 | Transgene Sa | Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique |
FR2760193B1 (fr) | 1997-02-28 | 1999-05-28 | Transgene Sa | Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules |
FR2763958A1 (fr) | 1997-05-29 | 1998-12-04 | Transgene Sa | Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique |
JP2002506436A (ja) | 1997-06-13 | 2002-02-26 | ザ ジョンズ ホプキンス ユニバーシティー | 治療用ナノスフェア |
CA2242035C (en) | 1997-07-01 | 2004-11-23 | Transgene S.A. | Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy |
DK1199368T3 (da) | 1998-07-07 | 2004-04-13 | Transgene Sa | Anvendelse af adenovirus-E4-læserammer til forbedring af ekspression af et gen af interesse |
WO2000050573A1 (fr) | 1999-02-22 | 2000-08-31 | Transgene S.A. | Procede d'obtention d'une preparation virale purifiee |
US6511832B1 (en) | 1999-10-06 | 2003-01-28 | Texas A&M University System | In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase |
EP1278551A2 (en) | 2000-04-21 | 2003-01-29 | Vical Incorporated | Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics |
AU2002307145B2 (en) * | 2001-04-05 | 2007-11-29 | The John Hopkins University | Chimeric vaccines |
EP1795599A1 (en) * | 2005-12-09 | 2007-06-13 | Schuler, Gerold, Prof. Dr. | Methods for generating antigen-specific effector T cells |
US9085638B2 (en) * | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
EP2161279A1 (en) * | 2008-08-29 | 2010-03-10 | Centre National de la Recherche Scientifique | Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies |
JP5933437B2 (ja) * | 2009-08-26 | 2016-06-08 | セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. | T細胞ヘルプを誘発する組成物 |
US20120294879A1 (en) * | 2009-10-13 | 2012-11-22 | National University Of Singapore | Consensus sequence for influenza a virus |
SG194099A1 (en) * | 2011-04-15 | 2013-11-29 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
LT2861240T (lt) * | 2012-06-15 | 2021-01-25 | Immunomic Therapeutics, Inc. | Nukleorūgštys skirtos alergijoms gydyti |
US11203629B2 (en) * | 2017-04-22 | 2021-12-21 | Immunomic Therapeutics, Inc. | LAMP constructs |
-
2018
- 2018-05-02 CN CN201880029699.0A patent/CN110913892A/zh active Pending
- 2018-05-02 US US16/610,133 patent/US20200087365A1/en active Pending
- 2018-05-02 AU AU2018263923A patent/AU2018263923B9/en active Active
- 2018-05-02 IL IL270271A patent/IL270271B2/en unknown
- 2018-05-02 KR KR1020197035028A patent/KR20200016224A/ko not_active Application Discontinuation
- 2018-05-02 KR KR1020247006135A patent/KR20240027895A/ko active Application Filing
- 2018-05-02 EP EP18729224.8A patent/EP3618854A1/en active Pending
- 2018-05-02 IL IL297073A patent/IL297073B2/en unknown
- 2018-05-02 WO PCT/US2018/030725 patent/WO2018204534A1/en unknown
- 2018-05-02 CA CA3061950A patent/CA3061950A1/en active Pending
- 2018-05-02 BR BR112019023014A patent/BR112019023014A2/pt unknown
- 2018-05-02 JP JP2019560156A patent/JP7222915B2/ja active Active
-
2022
- 2022-12-27 JP JP2022209238A patent/JP7407902B2/ja active Active
-
2023
- 2023-12-19 JP JP2023213451A patent/JP2024037951A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2018263923A1 (en) | 2019-10-31 |
EP3618854A1 (en) | 2020-03-11 |
JP2020518613A (ja) | 2020-06-25 |
AU2018263923B2 (en) | 2024-08-22 |
IL270271B (en) | 2022-11-01 |
IL270271A (pt) | 2019-12-31 |
IL297073B2 (en) | 2023-12-01 |
IL297073B1 (en) | 2023-08-01 |
IL270271B2 (en) | 2023-03-01 |
JP2024037951A (ja) | 2024-03-19 |
CN110913892A (zh) | 2020-03-24 |
CA3061950A1 (en) | 2018-11-08 |
KR20200016224A (ko) | 2020-02-14 |
WO2018204534A1 (en) | 2018-11-08 |
IL297073A (en) | 2022-12-01 |
JP7407902B2 (ja) | 2024-01-04 |
US20200087365A1 (en) | 2020-03-19 |
AU2018263923B9 (en) | 2024-09-19 |
JP7222915B2 (ja) | 2023-02-15 |
JP2023036863A (ja) | 2023-03-14 |
KR20240027895A (ko) | 2024-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019023014A2 (pt) | constructos de lamp aperfeiçoados compreendendo antígenos de câncer | |
CO2018012374A2 (es) | Moléculas de anticuerpo para el tratamiento del cáncer | |
BR112018015485A2 (pt) | imunoglobulina fabs-in-tandem e usos da mesma | |
CL2018001369A1 (es) | Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia de cáncer (divisional solicitud 201700836) | |
CL2019000146A1 (es) | Anticuerpos anti - gprc5d, moléculas de unión de antigeno bioespecificos que enlazan gprc5d y cd3, y usos relacionados. | |
CY1124896T1 (el) | Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων | |
SV2018005634A (es) | Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y usos de estos | |
BR112016015140A2 (pt) | imunoglobulina com fabs in-tandem e usos das mesmas | |
PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
BR112018074453A2 (pt) | proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral | |
MX2018014175A (es) | Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso. | |
BR112016016658A2 (pt) | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão | |
CU20170014A7 (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
UY36302A (es) | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas | |
BR112016018288A2 (pt) | proteínas de fusão de interleucina 2 e uso das mesmas | |
BR112017008696A2 (pt) | métodos e composições para células exterminadoras naturais | |
CL2015002246A1 (es) | Conjugados de anticuerpos drogas. | |
MX2021008334A (es) | Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco. | |
BR112017023374A2 (pt) | formulação de anticorpo anti-cgrp | |
BR112017008165A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
BR112019023990A2 (pt) | Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas | |
MA40612A (fr) | Nouveaux anticorps anti-mfi2 et méthodes d'utilisation | |
BR112017011556A2 (pt) | métodos para gerar um anticorpo sintético, prevenir ou tratar uma doença, tratar um sujeito de infecção por um patógeno e um sujeito com câncer, produto, molécula de ácido nucleico, e, composição. | |
CL2019000426A1 (es) | Anticuerpo o un fragmento de unión a antígeno del mismo, capaz de unirse a un receptor humano de interleucina-6. | |
BR112017013574A2 (pt) | conjugados de aminoácido e peptídeo e usos dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |